Filtr . . . while Potted agrees with much that you have to say . . . you're FORGETTING one BIG FACTOR . . . ISIS! . . . The FIRST company to effective RNA-drug DELIVERY . . . and that is undoubtedly ISIS . . . will likely build a STALWART MONOPOLY in the bio space! . . . effectively addressing the PRIZE-WINNING drug targets first ( e.g. the MOST PROMISING & MOST PROFITABLE targets ) . . . effectively shutting out "me-too" contenders like Alnylam!

Filtr . . if you studied Alnylam's drug delivery strategy . . . ( NOT a platform strategy in any sense ) . . . you would know that Alnylam needs a TAILORED delivery vehicle for EACH DRUG TARGET! . . . In Potted's view . . . THAT'S CRAZY! . . . the market will NOT wait 10 years for each tailored delivery vehicle to be identified, tested, and verified in HUMAN CLINICAL testing! ( that's what the Alnylam investor is looking at! ) . . . and especially when ISIS NOW HAS AN EFFECTIVE PLATFORM DELIVERY system with 2nd Generation Antisense for numerous targets . . . and with 3rd Generation Antisense - - 10 TIMES more powerful. . . just around the corner! - - ALSO A PLATFORM technology!

Given the current MULTITUDE of problems with double-stranded RNAi . . . which likely demands a TAILORED drug delivery system . . . Alnylam will NOT be able to effectively compete - IMO! . . . and that's why Alnylam . . . in the near future . . . will likely go "the ISIS Route" . . . with single-stranded RNAi . . . but in doing so . . . having to share HALF THE PIE with ISIS . . . can hardly be called a winning strategy!

Go to the Head-of-the-Class with ISIS!